CClinicalTrials.gg
Enrolling by invitationNCT06056960Updated Sep 28, 2023

Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part B

An interventional study of Tailored Physical Activity in Multiple Sclerosis, sponsored by Fondazione Don Carlo Gnocchi Onlus. Enrolling by invitation at 3 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 8 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

It is widely recognized that physical exercise is safe and people with moderate Multiple Sclerosis (MS) are encouraged to train regularly to improve their skills in motor task execution. Several studies demonstrated that these activities represent an effective low-cost therapy which leads to significant and clinically meaningful improvements in gait and balance in people with MS (PwMS) with mild to moderate walking dysfunction, possibly also by promoting brain plasticity.

There is general agreement within the scientific community on the importance of timing intervention also during the early stages of MS to preserve or improve walking and balance abilities and fostering brain functional adaptation, thus slowing down the disease progression. Previous studies highlighted the need to early identify and manage gait disorders using a multimodal approach tailored on individual's need. Moreover, Functional Near-Infrared Spectroscopy (fNIRS) measures blood flow which accompanies neuronal activity and thus, it can provide spatial information about changes in cortical activation patterns due to the possible effects of exercise on cortical plasticity.

To the best of the investigators knowledge, no published studies have assessed the effect of exercise on mobility and brain activity in PwMS with minimal or clinically undetectable disability. This emphasizes the need of trials investigating the effect of walking exercise as preventive strategy on MS clinical worsening.

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • early phase
  • non-disabled
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 80 is above the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Fondazione Don Carlo Gnocchi Onlus is the lead sponsor of 146 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age > 17 years
  • Stable disease course (without worsening over 1 point at the Expanded Disability Status Scale in the last 3 months)

Exclusion criteria

Exclusion Criteria:

  • Major depression
  • Mini-Mental State Examination \< 27
  • Other cardiovascular or orthopedic diseases that interfere with physical exercise
  • Progressive course of the disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Physical Activity

    The experimental group will perform a combination of endurance and balance training tailored to the subject.

    Other: Tailored Physical Activity

  • No intervention
    Usual Activity

    The control group will perform their usual daily activities.

Interventions

  • OtherTailored Physical Activity

    The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR. Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem.

06

What researchers measure

Primary outcomes

  1. Fatigue Severity Scale (FSS)

    Is a 9-item self-administered questionnaire to measure the perceived impact of fatigue. The minimum score is 9 and maximum score possible is 63. Higher scores represent greater fatigue severity. If the score is calculated as the mean score of the 9 items, the cut-off score for the presence of the symptom fatigue is set as scores higher than 4.

    Time frame: Baseline, Post, FollowUp_6month

Secondary outcomes

  1. Differences in oxygenated hemoglobin (Delta oxyHb)

    The differences in oxyHb during task period and resting state. Data will be extracted from functional Near InfraRed Spectroscopy (fNIRS) assessment.

    Time frame: Baseline, Post, FollowUp_6month

  2. Six Minute walking test (6MWT)

    Gait asymmetry and regularity extracted from Inertial Measurement Unit's during the six minute walking test.

    Time frame: Baseline, Post, FollowUp_6month

  3. Number of steps/day

    Assessed by activity trackers, a non-invasive method of monitoring human rest/activity cycles. Subjects will be monitored for 1 week wearing an actigraph.

    Time frame: Baseline, Post, FollowUp_6month

  4. Endurance walking capacity

    Assessed as the distance walked over 6 minutes as a sub-maximal test of endurance (6MWT).

    Time frame: Baseline, Post, FollowUp_6month

07

Study locations

3 sites
  • Ospedale Binaghi ASL Cagliari
    Cagliari, Italy
  • IRCCS Ospedale San Raffele
    Milan, 20100, Italy
  • IRCCS Fondazione Don Carlo Gnocchi
    Milan, 20148, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06056960
Lead sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
IRCCS San Raffaele, Azienda Sanitaria Locale di Cagliari
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Jul 15, 2024 (estimated)
Primary completion
Jan 30, 2025 (estimated)
Completion
Jan 30, 2025 (estimated)
Last update
Sep 28, 2023

Study contacts

Marco Rovaris, MD
principal investigator · IRCCS Fondazione Don Carlo Gnocchi
Raffaella Chieffo, MD
principal investigator · IRCCS Ospedale San Raffaele
Eleonora Cocco, MD
principal investigator · Ospedale Binaghi ASL Cagliari, Sardegna

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion